Dupilumab for the treatment of prurigo nodularis: A systematic review

Conventional treatment techniques have limited efficacy and more side effects in the treatment of prurigo nodularis. The better alternative treatment option for better outcomes of the disease is dupilumab. The objective of this study was to systematically review dupilumab-related treatment outcomes...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1092685
Main Authors Cao, Peng, Xu, Wenjing, Jiang, Shuyi, Zhang, Litao
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 20.01.2023
Subjects
Antibodies, Monoclonal, Humanized - adverse effects
biologics
dupilumab
Humans
Immunology
itch
Prurigo - chemically induced
Prurigo - drug therapy
prurigo nodularis
Pruritus - drug therapy
treatment
Treatment Outcome
itch
treatment
biologics
prurigo nodularis
dupilumab
Online AccessGet full text

Cover

More Information
Summary:Conventional treatment techniques have limited efficacy and more side effects in the treatment of prurigo nodularis. The better alternative treatment option for better outcomes of the disease is dupilumab. The objective of this study was to systematically review dupilumab-related treatment outcomes in prurigo nodularis. Several databases like Embase, PubMed, Web of Science, and Cochrane library were searched for data acquisition on October 8, 2022. Based on Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, 24 publications were included in this study. After 4,12,16 and more than 16 weeks of dupilumab treatment, 8.3% (n=5/60), 34.4% (n=11/32), 3.6% (n=2/56), and 45.3% (n=29/64) of patients had complete remission, respectively. In addition, 85.0% (n=51/60), 59.4% (n=19/32), 83.9% (n=47/56), and 43.8% (n=28/64) had partial remission, respectively. Moreover, 6.7% (n=4/60), 6.3% (n=2/32), 12.5% (n=7/56), and 10.9% (n=7/64) showed no remission, respectively, and significant reduction of numeric rating scale itch intensity (from 9.0 to 4.9, 2.1, 2.8, 0.9) was attained. There were no serious adverse events observed during treatment, but the most common event observed was conjunctivitis (12.6%, n=15/119). Dupilumab has definite effectiveness and safety in prurigo nodularis treatment. https://www.crd.york.ac.uk/PROSPERO, identifier (CRD42022365802).
Bibliography:content type line 23
SourceType-Scholarly Journals-1
Edited by: Angelo Valerio Marzano, University of Milan, Italy
This article was submitted to Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders, a section of the journal Frontiers in Immunology
Reviewed by: Gianluca Avallone, University of Turin, Italy; Carlo Alberto Maronese, Ca ‘Granda Foundation Maggiore Policlinico Hospital (IRCCS), Italy
These authors have contributed equally to this work and share first authorship
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1092685